Value Added Services in Cardiometabolic Diseases -- Payer views

Value Added Services in Cardiometabolic Diseases -- Payer views

  • October 2017 •
  • Report ID: 5214611 •
  • Format: PDF
Pharma’s Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post launch. No wonder there is a widespread cynical view among payers that many "beyond the pill" support services are little more than a marketing ploy. How can Pharma get back on track and deliver sustained VAS that innovatively support long-term cardiometabolic disease patients, change behaviour and build trust with payers? Value-added Services in Cardiometabolic Diseases meets head-on the current criticism of many VAS initiatives, and through the hard-hitting insights of senior US and EU payers, clearly identifies the key VAS design, development and areas for improvement that industry needs to address.

Answering key questions:

Reasons to buy this report
VAS have become a standard feature of pharma’s outreach and companies can point to a raft of monitoring, education and health support services that have made a real impact. So why are payers sceptical and how is that impacting pharma’s prospects? Short lived VAS are not building trust with payers or fully meeting the long-term needs of patients – especially in chronic conditions such as diabetes. It can be better. In this report experienced US and EU payers identify what good, on-target VAS look like, how working with payers can lead to better VAS solutions and how sharing outcomes data can help prove product value to a company’s commercial benefit.

This report will enable you to:
• Plan VAS into the product lifecycle to support patients with chronic cardiometabolic diseases
• Leverage real world VAS outcomes data to support value claims with payers
• Work collaboratively with payers to design innovative VAS programmes
• Learn why working with trusted independent 3rd parties to deliver VAS will gain payer approval
• Innovate to address non-adherence in a patient-centric way
• Understand how US and EU5 payers’ views of VAS vary and nuance your programmes to meet local conditions